Based on Therapeutic Conditions, Gaucher's Disease Segment to Account for Largest Share of Enzyme Replacement Therapy Market During 2022-2028

According to our latest study on "Enzyme Replacement Therapy Market Forecast to 2028 - COVID-19 Impact and Global Analysis - by Enzyme Type, Therapeutic Conditions, Route of Administration, and End User," the market is projected to reach US$ 15,184.70 million by 2028 from US$ 9,673.39 million in 2021; it is expected to grow at a CAGR of 6.8% from 2022 to 2028. The report highlights the key factors driving the market growth and prominent players with their developments in the market.

The COVID-19 pandemic significantly decreased the adoption of enzyme replacement therapy. The pandemic altered economic conditions and social behaviors in all regions. Containment measures enacted by governments to mitigate the spread of novel coronavirus changed the healthcare service delivery pattern in the US. According to the Department of Emergency Medicine, in many cities across the country, emergency department (ED) visits decreased by ~40% in 2020. Moreover, outpatient appointments and elective treatments were postponed or replaced by telemedicine practices. Thus, the factors mentioned above hindered the growth of the global enzyme replacement therapy market during the COVID-19 pandemic.

Based on enzyme type, the global enzyme replacement therapy market is segmented into alglucosidase alfa, velaglucerase alfa, agalsidase beta, imiglucerase, galsulfase, idursulfase, and other enzymes. The other enzymes segment is likely to account for the largest market share during 2022-2028. By therapeutic conditions, the market is segmented into Gaucher's disease, Fabry's Disease, Pompe's Disease, SCID, MPS, and other therapeutic conditions. The Gaucher's disease segment held the largest market share in 2021 and is likely to continue its dominance during the forecast period. Based on route of administration, the global enzyme replacement therapy market is segmented into oral and parenteral. The parenteral segment is likely to account for a larger market share during 2022-2028. By end user, the market is segmented into hospitals, infusion centers, and others. The hospitals segment held the largest market share in 2021 and is likely to continue its dominance during the forecast period.

In February 2022, the study on "Antibodies against recombinant human alpha-glucosidase do not seem to affect clinical outcome in childhood-onset Pompe disease" published in Orphanet Journal of Rare Diseases found that many children suffering from Pompe's disease had developed antibodies against Myozyme (alglucosidase alfa) enzyme replacement therapy but the presence of antibodies did not hamper the treatment efficacy of enzymes. Thus, the higher efficacy of the enzyme will enhance its adaptability among the population, which supports the market growth.

Takeda Pharmaceutical Company Limited; Sanofi; AbbVie Inc.; BioMarin Pharmaceutical Inc.; Amicus Therapeutics; Alexion Pharmaceuticals, Inc. (AstraZeneca); Janssen Pharmaceuticals (Johnson and Johnson Services, Inc.); Recordati S.p.A.; Pfizer Inc.; and CHIESI Farmaceutici S.p.A. are among the leading companies operating in the global enzyme replacement therapy market.

In terms of geography, the report segments the global enzyme replacement therapy market as follows:

Based on geography, the global enzyme replacement therapy market is primarily segmented into North America, Europe, Asia Pacific, Middle East and Africa (MEA), and South and Central America. The market in North America is further segmented into the US, Canada, and Mexico. The European market is subsegmented into France, Germany, the UK, Spain, Italy, and the Rest of Europe. The market in Asia Pacific is subsegmented into Japan, China, India, Australia, South Korea, and the Rest of APAC. The enzyme replacement therapy market in the MEA is further segmented into Saudi Arabia, the UAE, South Africa, and the Rest of MEA. The market in South and Central America is subsegmented into Brazil, Argentina, and the Rest of South and Central America.

Contact Us
Contact Person: Sameer Joshi
Phone: +1-646-491-9876
Email Id: sales@premiummarketinsights.com